Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
GVS S.p.A. is an Italy-based manufacturer specializing in highly technological filtration solutions and components for diverse applications. The company produces advanced filters and systems primarily for the healthcare sector, including MedTech for life-saving technologies, Transfusion Medicine for blood safety, and Life Sciences for biology, chemistry, diagnostics, and bioprocessing. It also serves Safety with high-performance protective devices for workplaces, and Energy & Mobility with filtration for energy systems and sustainable mobility. GVS S.p.A. operates through multiple divisions, maintaining a glocal approach with production plants in Italy, the United Kingdom, Brazil, the United States, China, Mexico, Romania, and Puerto Rico, alongside commercial offices worldwide. Founded in 1979 and headquartered in Zola Predosa near Bologna, the company emphasizes research, development, and innovation to deliver precision solutions across healthcare equipment, automotive, appliance, and industrial markets.
13.91% operating margin is respectable but not wide. ROIC at 5.45%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 0.9% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 81% versus the prior year, cash generation momentum has weakened. Net debt of €229M represents 20.4x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
€425M
▼ -0.9% YoY
Net Income (TTM)
€18M
▼ -44.8% YoY
Op. Margin
13.91%
▲ +0.2pp YoY
ROIC
5.45%
Cash Flow & Balance Sheet
FCF (TTM)
€11M
▼ -81.1% YoY
Op. Cash Flow (TTM)
€47M
▼ -31.3% YoY
Net Debt
€229M
Cash & Equiv.
€81M
3Y CAGR: +2.9%
3Y CAGR: -40.4%
Continue Research